Aliases & Classifications for Toxic Shock Syndrome

MalaCards integrated aliases for Toxic Shock Syndrome:

Name: Toxic Shock Syndrome 12 52 14 69
Staphylococcal Toxic Shock Syndrome 69
Shock, Septic 42
Toxic Shock 12
Tss 12

Classifications:



External Ids:

Disease Ontology 12 DOID:14115
ICD10 33 A48.3 R57.2
ICD9CM 35 040.82
MeSH 42 D012772
NCIt 47 C35498
SNOMED-CT 64 18504008
UMLS 69 C0600327

Summaries for Toxic Shock Syndrome

Disease Ontology : 12 A commensal bacterial infectious disease that results_in infection, has material basis in Streptococcus pyogenes or has material basis in Staphylococcus aureus , which produce toxins that are absorbed systemically and produce the systemic manifestations. The infection has symptom fever, has symptom rash, has symptom hypotension, has symptom multiorgan failure, has symptom desquamation, has symptom vomiting, has symptom diarrhea, has symptom headache, and has symptom nonfocal neurologic abnormalities.

MalaCards based summary : Toxic Shock Syndrome, also known as staphylococcal toxic shock syndrome, is related to hepatitis b and hemophagocytic lymphohistiocytosis, and has symptoms including shock without mention of trauma An important gene associated with Toxic Shock Syndrome is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Ceftriaxone and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and lung, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Wikipedia : 72 Toxic shock syndrome (TSS) is a condition caused by bacterial toxins. Symptoms may include fever, rash,... more...

Related Diseases for Toxic Shock Syndrome

Diseases related to Toxic Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 414)
id Related Disease Score Top Affiliating Genes
1 hepatitis b 29.5 CXCL8 IFNG IL10 TNF
2 hemophagocytic lymphohistiocytosis 29.3 IFNG IL10 IL2 IL6 TNF
3 scabies 28.9 CXCL8 IFNG IL10 IL1B IL6 TNF
4 choroiditis 28.6 CXCL8 IL10 IL1B IL6 TLR4 TNF
5 systemic lupus erythematosus 26.7 C1S HMGB1 IFNG IL10 IL2 IL4
6 colorectal cancer 26.7 CXCL8 HMGB1 IFNG IL10 IL1B IL2
7 rheumatoid arthritis 26.5 CIITA CXCL8 HMGB1 IFNG IL10 IL1B
8 staphylococcal toxic shock syndrome 12.5
9 streptococcal toxic-shock syndrome 12.3
10 clostridium sordellii infection 11.3
11 scirrhous adenocarcinoma 10.9 IL2 TNF
12 kallmann syndrome 3 10.8 IL2 LTA
13 smarca4-deficient sarcoma of thorax 10.8 IL6 TNF
14 tabatznik syndrome 10.8 IL1B TNF
15 aortic arch interruption 10.7 IL6 TNF
16 scrotal carcinoma 10.7 IL1B IL6 TNF
17 cutaneous leishmaniasis 10.7 IL6 TNF
18 pure autonomic failure 10.7 IL10 TNF
19 toxoplasmosis 10.7 IL6 LTA TNF
20 upper gum cancer 10.7 IL1B IL6 TNF
21 central nervous system leiomyosarcoma 10.7 IL1B IL6 TNF
22 stargardt macular degeneration absent or hypoplastic corpus callosum mental retardation and dysmorphic features 10.7 IL1B IL6 TNF
23 congenital diaphragmatic hernia 10.7 CXCL8 IL2
24 ampulla of vater neoplasm 10.7 IL1B IL6 TNF
25 benign neonatal seizures 10.7 IL1B IL6 TNF
26 keloids 10.7 IL1B IL6 TNF
27 myoclonic astatic epilepsy 10.7 IFNG IL4
28 brucella canis brucellosis 10.7 IL1B IL6 TNF
29 human monocytic ehrlichiosis 10.7 IL1B IL6 TNF
30 x-linked dominant intellectual disability-epilepsy syndrome 10.7 IL1B IL2 IL6
31 osmotic diarrhea 10.7 IL1B IL6 TNF
32 epulis 10.7 CXCL8 IL1B TNF
33 oculomotor nerve paralysis 10.6 CXCL8 IL1B IL6
34 common peroneal nerve lesion 10.6 CXCL8 IL1B IL6
35 cytomegalovirus disease in patients with impaired cell mediated immunity deemed at risk 10.6 CIITA IL6 TNF
36 pancreas lymphoma 10.6 IL1B IL6 TNF
37 cicatricial lagophthalmos 10.6 CXCL8 IL6 TNF
38 early congenital syphilis 10.6 IL2 IL6 TNF
39 autoimmune polyglandular syndrome type 3 10.6 IFNG IL2 TNF
40 bullous retinoschisis 10.6 CXCL8 IL1B IL6
41 uterine adnexa cancer 10.6 IL1B IL6 TNF
42 carbuncle 10.6 CXCL8 IL1B IL6
43 pulmonary hypertension 10.6 IL1B TNF
44 visual snow syndrome 10.6 IL2 IL4
45 esophagus leiomyoma 10.6 CXCL8 IL6 TNF
46 parametritis 10.6 IFNG IL2 TNF
47 tibialis tendinitis 10.6 CXCL8 IL1B TNF
48 whistling face syndrome, recessive form 10.6 CXCL8 IL1B IL2
49 bolivian hemorrhagic fever 10.6 IFNG IL2 TNF
50 sinusitis 10.6 CXCL8 IL1B TNF

Graphical network of the top 20 diseases related to Toxic Shock Syndrome:



Diseases related to Toxic Shock Syndrome

Symptoms & Phenotypes for Toxic Shock Syndrome

UMLS symptoms related to Toxic Shock Syndrome:


shock without mention of trauma

GenomeRNAi Phenotypes related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CXCL8 IL10 IL1B IL2 LTA TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 CXCL8 IL10 IL1B IL2 LTA TNF

MGI Mouse Phenotypes related to Toxic Shock Syndrome:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.29 CIITA EDNRA IFNG IL10 IL1B IL2
2 homeostasis/metabolism MP:0005376 10.27 TLR4 TNF CIITA EDNRA IFNG IL10
3 immune system MP:0005387 10.26 CIITA EDNRA IFNG IL10 IL1B IL2
4 cardiovascular system MP:0005385 10.25 EDNRA IFNG IL10 IL1B IL2 IL6
5 endocrine/exocrine gland MP:0005379 10.18 CIITA EDNRA IFNG IL10 IL2 IL4
6 digestive/alimentary MP:0005381 10.14 TLR4 TNF EDNRA IFNG IL10 IL2
7 mortality/aging MP:0010768 10.14 EDNRA IFNG IL10 IL1B IL2 IL4
8 liver/biliary system MP:0005370 10.09 IL2 IL4 IL6 LTA SERPINC1 TLR4
9 integument MP:0010771 10.06 EDNRA IFNG IL10 IL1B IL4 IL6
10 nervous system MP:0003631 10.02 TNF EDNRA IFNG IL10 IL1B IL4
11 neoplasm MP:0002006 9.91 IFNG IL10 IL1B IL2 IL6 TLR4
12 reproductive system MP:0005389 9.86 IFNG IL10 IL2 IL4 IL6 SERPINC1
13 respiratory system MP:0005388 9.81 EDNRA IFNG IL10 IL2 IL4 IL6
14 skeleton MP:0005390 9.65 CIITA EDNRA IFNG IL10 IL1B IL4
15 vision/eye MP:0005391 9.32 EDNRA IFNG IL10 IL2 IL4 IL6

Drugs & Therapeutics for Toxic Shock Syndrome

Drugs for Toxic Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
2
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
3
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
4
Rifampin Approved Phase 4 13292-46-1 5458213 5381226
5
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
6
Propafenone Approved Phase 4 54063-53-5 4932
7
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
8 Anti-Bacterial Agents Phase 4
9 Anti-Infective Agents Phase 4
10 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
11 Anti-Arrhythmia Agents Phase 4,Phase 3
12 Antibodies Phase 4,Phase 2
13 gamma-Globulins Phase 4,Phase 2
14 Immunoglobulins Phase 4,Phase 2
15 Immunoglobulins, Intravenous Phase 4,Phase 2
16 Rho(D) Immune Globulin Phase 4,Phase 2
17 Amoxicillin-Potassium Clavulanate Combination Phase 4
18 Antibiotics, Antitubercular Phase 4
19 beta-Lactamase Inhibitors Phase 4
20 Clavulanic Acid Phase 4
21 Clindamycin palmitate Phase 4
22 Clindamycin phosphate Phase 4
23 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
24 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
25 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
26 Cytochrome P-450 CYP3A Inhibitors Phase 4
27 Cytochrome P-450 Enzyme Inhibitors Phase 4
28 Diuretics, Potassium Sparing Phase 4
29 Potassium Channel Blockers Phase 4
30 Sodium Channel Blockers Phase 4
31 Vasodilator Agents Phase 4
32 proline Nutraceutical Phase 4
33
Nitric Oxide Approved Phase 3 10102-43-9 145068
34
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078 2978
35 Analgesics Phase 3
36 Analgesics, Non-Narcotic Phase 3
37 Antiemetics Phase 3
38 Autonomic Agents Phase 3
39 Cannabinoid Receptor Agonists Phase 3
40 Excitatory Amino Acid Antagonists Phase 3
41 Excitatory Amino Acids Phase 3
42 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
43 Hallucinogens Phase 3
44 Hormone Antagonists Phase 3
45 Hormones Phase 3
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
47 HU 211 Phase 3 112924-45-5
48 Neuroprotective Agents Phase 3
49 Neurotransmitter Agents Phase 3,Phase 1
50 Peripheral Nervous System Agents Phase 3

Interventional clinical trials:

(show all 48)

id Name Status NCT ID Phase Drugs
1 Pharmacokinetic of Ceftriaxone in Septic ICU Patients Unknown status NCT00449800 Phase 4 ceftriaxone
2 Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children Not yet recruiting NCT02899702 Phase 4 PRIVIGEN (CSL Behring);Albumin
3 Propafenone Versus Amiodarone in Septic Shock Not yet recruiting NCT03029169 Phase 4 Propafenone i.v.;Amiodarone i.v.
4 Safety and Efficacy of PHP in the Treatment of Shock Associated With Systemic Inflammatory Response Syndrome (SIRS) Completed NCT00021502 Phase 3 pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)
5 Dexanabinol in Severe Traumatic Brain Injury Completed NCT00129857 Phase 3 Dexanabinol
6 Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias Not yet recruiting NCT01013714 Phase 3 Routine Care
7 GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma Completed NCT00293423 Phase 1, Phase 2
8 Sodium Bicarbonate in Cardiac Surgery Completed NCT00334191 Phase 2 Sodium Bicarbonate;Placebo
9 Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Completed NCT01780545 Phase 2 OGX-427;Docetaxel
10 Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study Recruiting NCT02219165 Phase 2 Intravenous human immunoglobulin;Albumin
11 Clinical Trial of the BioMed rTSST‐1 Variant Vaccine in Healthy Adults Recruiting NCT02814708 Phase 2
12 Rapid Administration of Carnitine in sEpsis Recruiting NCT01665092 Phase 2 Levo-Carnitine;placebo
13 Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis Terminated NCT01353638 Phase 1, Phase 2 Dipeptiven (Alanyl-glutamine-dipeptide)
14 STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma Terminated NCT01551693 Phase 2 STA-9090
15 A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma Terminated NCT00627419 Phase 2 IPI-504
16 PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer Terminated NCT01227018 Phase 2 STA-9090
17 A Study for Treatment of Superficial Bladder Cancer Using OGX-427 Unknown status NCT00959868 Phase 1 OGX-427
18 The Impact of Zinc Supplementation on Innate Immunity and Patient Safety in Sepsis Unknown status NCT02130388 Phase 1
19 Phase I STEBVax in Healthy Adults Completed NCT00974935 Phase 1 Aluminum hydroxide
20 Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial Completed NCT02971670 Phase 1
21 rTSST-1 Variant Vaccine Phase 1 First-in-man Trail Completed NCT02340338 Phase 1
22 Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults Completed NCT01717950 Phase 1
23 Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase Completed NCT00027144 Phase 1
24 Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia Completed NCT00030303 Phase 1
25 A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1) Completed NCT01951560 Phase 1 Valproic Acid;Isotonic saline solution
26 Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors Completed NCT01892046 Phase 1 SNX-5422
27 Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma Completed NCT01851096 Phase 1 SNX-5422
28 Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting NCT02503709 Phase 1 CDKI AT7519;Onalespib
29 Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin Active, not recruiting NCT02381535 Phase 1 Cisplatin;Onalespib
30 Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Active, not recruiting NCT02060253 Phase 1 ganetespib;paclitaxel
31 A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2) Enrolling by invitation NCT02872428 Phase 1 Valproic Acid;Isotonic saline solution
32 A Study of DS-2248, in Subjects With Advanced Solid Tumors Terminated NCT01288430 Phase 1 DS-2248
33 Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Withdrawn NCT02627430 Phase 1 Hsp90 Inhibitor AT13387;Talazoparib
34 Predictive Value of Troponin I for Acute Respiratory Distress Syndrome in Children With Shock Unknown status NCT02361840
35 Role of Beta-blockers in the Prevention on the Arisen of a Severe Sepsis (TESS) Completed NCT01606631
36 Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract Completed NCT00299663
37 Surveillance of Streptococcal Infections in Children in India Completed NCT00342199
38 Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus Completed NCT01141101
39 Catecholamine-O-Methyl-Transferase(COMT)-Polymorphism in Cardiac Surgery Completed NCT00334009
40 Impact of Therapeutic Drug Monitoring on Anti-Infective Agents Amongst Severely Burned Patients Requiring ICU Admission Completed NCT01965340
41 Pediatric Immune Response to Infectious Shock Recruiting NCT02848144
42 Severe Soft Tissue Infections: Perspectives of Patients and Significant Others Recruiting NCT02169128
43 Bronchial Mapping (GCC 1635) Recruiting NCT02745548
44 Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma Active, not recruiting NCT00568763
45 Beta-Lactam InfusioN Group Study Not yet recruiting NCT03213990
46 ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber Terminated NCT02335723
47 Intra Peritoneal Chemo Hyperthermia (IPCH) : Cellular and Metabolic Consequences Terminated NCT01685632
48 Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant Recipients Withdrawn NCT00709293 Anti-Thymocyte Globulin;Normal Saline

Search NIH Clinical Center for Toxic Shock Syndrome

Cochrane evidence based reviews: shock, septic

Genetic Tests for Toxic Shock Syndrome

Anatomical Context for Toxic Shock Syndrome

MalaCards organs/tissues related to Toxic Shock Syndrome:

39
T Cells, Skin, Lung, Colon, Monocytes, Pancreas, Brain

Publications for Toxic Shock Syndrome

Articles related to Toxic Shock Syndrome:

(show top 50) (show all 696)
id Title Authors Year
1
Toxic shock syndrome - the seven Rs of management and treatment. ( 28646955 )
2017
2
Group B Streptococcal Toxic Shock Syndrome and covR/S Mutations Revisited. ( 27983484 )
2017
3
Streptococcal Toxic Shock Syndrome Caused by Group G Streptococcus, United Kingdom. ( 27983491 )
2017
4
Group A Streptococcal Peritonitis and Toxic Shock Syndrome in a Postmenopausal Woman. ( 28824068 )
2017
5
Toxic shock syndrome due to community-acquired methicillin-resistant Staphylococcus aureus infection: Two case reports and a literature review in Japan. ( 28491813 )
2017
6
Streptococcal toxic-shock syndrome due to Streptococcus dysgalactiae subspecies equisimilis in breast cancer-related lymphedema: a case report. ( 28705211 )
2017
7
A 2-year-old boy with circulatory failure owing to streptococcal toxic shock syndrome: case report. ( 28426384 )
2017
8
Two Catastrophes in One Patient: Drug Reaction with Eosinophilia and Systemic Symptoms and Toxic Shock Syndrome. ( 28721327 )
2017
9
HLA-DR polymorphisms influence in vivo responses to staphylococcal toxic shock syndrome toxin-1 in a transgenic mouse model. ( 27863161 )
2017
10
Successful Treatment of Necrotizing Fasciitis and Streptococcal Toxic Shock Syndrome with the Addition of Linezolid. ( 28299216 )
2017
11
Inverse relationship between toxic shock syndrome toxin-1 antibodies and interferon-I^ and interleukin-6 in peripheral blood mononuclear cells from patients with pediatric tonsillitis caused by Staphylococcus aureus. ( 28483238 )
2017
12
Streptococcal toxic shock syndrome occurring in the third trimester of pregnancy: A case report. ( 28762570 )
2017
13
Toxic shock syndrome caused by suture abscess with methicillin-resistant Staphylococcus aureus (MRSA) with late onset after Caesarean section. ( 28791216 )
2017
14
Use of Hemadsorption in a Case of Pediatric Toxic Shock Syndrome. ( 28791185 )
2017
15
Toxic shock syndrome, tampons and laboratory standard-setting. ( 28536130 )
2017
16
Toxic Shock Syndrome within 24 H of an Office Hysteroscopy. ( 28706411 )
2017
17
Toxic shock syndrome in paediatric thermal injuries: A case series and systematic literature review. ( 28867411 )
2017
18
Pleural empyema and streptococcal toxic shock syndrome due to Streptococcus pyogenes in a healthy Spanish traveler in Japan. ( 28725562 )
2017
19
Case of toxic shock syndrome triggered by negative-pressure wound therapy. ( 28862320 )
2017
20
Prevalence, comorbidities and mortality of toxic shock syndrome in United States children and adults. ( 28892185 )
2017
21
Intense, flu-like symptoms in women using menstrual devices: always think of staphylococcal Toxic Shock Syndrome. ( 28580155 )
2017
22
Complete Genome Sequence and Comparative Genomics of a Streptococcus pyogenes emm3 Strain M3-b isolated from a Japanese Patient with Streptococcal Toxic Shock Syndrome. ( 28698738 )
2017
23
Post-partum streptococcal toxic shock syndrome associated with necrotizing fasciitis. ( 28725564 )
2017
24
Vaccine against toxic shock syndrome in a first-in-man clinical trial. ( 27918218 )
2017
25
Erratum: Intense, flu-like symptoms in women using menstrual devices: always think of staphylococcal Toxic Shock Syndrome. ( 28721224 )
2017
26
Local Epidermal Growth Factor Receptor Signaling Mediates the Systemic Pathogenic Effects of Staphylococcus aureus Toxic Shock Syndrome. ( 27414801 )
2016
27
Poster 80 Bilateral Lower Extremity Amputation after Toxic Shock Syndrome Presents with Locked Knee: AA Case Report. ( 27672849 )
2016
28
Right in Front of Our Eyes: Evolution of Streptococcal Toxic Shock Syndrome with Ischemic Optic Neuropathy. ( 27903001 )
2016
29
Lipopolysaccharide-Induced Toxic Shock Syndrome in Rabbits. ( 26676037 )
2016
30
The SaeRS Two-Component System Is a Direct and Dominant Transcriptional Activator of Toxic Shock Syndrome Toxin 1 in Staphylococcus aureus. ( 27457715 )
2016
31
Cytokine profile and T cell receptor analysis in a case of postpartum toxic shock syndrome. ( 27154311 )
2016
32
Acute encephalopathy with biphasic seizures and late reduced diffusion associated with staphylococcal toxic shock syndrome caused by burns. ( 27117386 )
2016
33
Swift Intrahepatic Accumulation of Granulocytic Myeloid-Derived Suppressor Cells in a Humanized Mouse Model of Toxic Shock Syndrome. ( 26908735 )
2016
34
Polymyxin-B immobilized column-direct hemoperfusion for adolescent toxic shock syndrome. ( 27804246 )
2016
35
Preliminary investigation of human serum albumin-VI^ inhibition on toxic shock syndrome induced by staphylococcus enterotoxin B inA vitro and inA vivo. ( 26792715 )
2016
36
Clostridium Sordellii as an Uncommon Cause of Fatal Toxic Shock Syndrome in a Postpartum 33-Year-Old Asian Woman, and the Need for Antepartum Screening for This Clostridia Species in the General Female Population. ( 27371657 )
2016
37
Mild forms of toxic shock syndrome toxin-1-mediated exanthematous disease related to Staphylococcus aureus infection. ( 26923257 )
2016
38
A fatal case of streptococcal toxic shock syndrome caused by Streptococcus suis carrying tet (40) and tet (O/W/32/O), Italy. ( 27553071 )
2016
39
Relevance of spontaneous fabT mutations to a streptococcal toxic shock syndrome to non-streptococcal toxic shock syndrome transition in the novel-type Streptococcus pyogenes isolates that lost a salRK. ( 26861052 )
2016
40
Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial. ( 27296693 )
2016
41
A Term Infant of Neonatal Toxic Shock Syndrome-Like Exanthematous Disease Complicated with Hemophagocytic Syndrome. ( 27760897 )
2016
42
Intrauterine device infection causing concomitant streptococcal toxic shock syndrome and pelvic abscess with Actinomyces odontolyticus bacteraemia. ( 26965406 )
2016
43
Recurrent SDSE bacteraemia resulting in streptococcal toxic shock syndrome in a patient with Noonan syndrome. ( 27485878 )
2016
44
Streptococcal Toxic Shock Syndrome: Life Saving Role of Peritoneal Lavage and Drainage. ( 27579001 )
2016
45
Profuse watery diarrhoea: An unusual presenting feature of streptococcal toxic shock syndrome. ( 27124845 )
2016
46
High prevalence of toxic shock syndrome toxin-producing epidemic methicillin-resistant Staphylococcus aureus 15 (EMRSA-15) strains in Kuwait hospitals. ( 27222714 )
2016
47
Toxic Shock Syndrome Caused by Methicillin-Resistant Staphylococcus aureus (MRSA) After Expander-Based Breast Reconstruction. ( 26813150 )
2016
48
Clinically mild encephalitis/encephalopathy with a reversible splenial lesion caused by methicillin-sensitive Staphylococcus aureus bacteremia with toxic shock syndrome: a case report. ( 27091490 )
2016
49
Toxic Shock Syndrome: An Unusual Organism. ( 27432040 )
2016
50
Invariant NKT cells are pathogenic in the HLA-DR4-transgenic humanized mouse model of toxic shock syndrome and can be targeted to reduce morbidity. ( 28035011 )
2016

Variations for Toxic Shock Syndrome

Expression for Toxic Shock Syndrome

Search GEO for disease gene expression data for Toxic Shock Syndrome.

Pathways for Toxic Shock Syndrome

Pathways related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 C1S CIITA CXCL8 HMGB1 IFNG IL10
2
Show member pathways
13.76 CXCL8 EDNRA IFNG IL10 IL1B IL2
3
Show member pathways
13.62 CXCL8 IFNG IL10 IL1B IL2 IL4
4
Show member pathways
13.51 CXCL8 IL10 IL1B IL2 IL4 IL6
5
Show member pathways
13.47 CIITA CXCL8 IFNG IL10 IL1B IL2
6
Show member pathways
13.39 CXCL8 IL10 IL1B IL2 IL4 IL6
7
Show member pathways
13.27 HMGB1 IFNG IL1B IL2 IL4 TLR4
8
Show member pathways
13.02 CXCL8 IFNG IL10 IL1B IL2 IL6
9
Show member pathways
12.9 CIITA CXCL8 IFNG IL10 IL1B IL2
10
Show member pathways
12.84 IL2 IL4 IL6 LTA TNF
11
Show member pathways
12.83 CXCL8 HMGB1 IFNG IL1B IL6 TNF
12
Show member pathways
12.82 CIITA CXCL8 IFNG IL1B IL2 IL4
13
Show member pathways
12.81 IL1B IL2 IL6 LTA TLR4 TNF
14
Show member pathways
12.74 IFNG IL10 IL1B IL2 IL4 IL6
15
Show member pathways
12.71 IFNG IL10 IL1B IL2 IL6 TNF
16
Show member pathways
12.7 IFNG IL10 IL2 IL4 TNF
17 12.69 CIITA IFNG IL10 IL1B IL2 IL4
18
Show member pathways
12.59 IFNG IL10 IL1B IL2 IL4 IL6
19
Show member pathways
12.54 IFNG IL2 IL4 TNF
20
Show member pathways
12.49 CXCL8 IFNG IL1B IL4 IL6 TNF
21 12.46 IL2 IL6 LTA TNF
22
Show member pathways
12.43 CXCL8 IFNG IL1B IL6 TLR4 TNF
23
Show member pathways
12.41 CIITA IFNG IL10 IL1B IL4 TLR4
24 12.37 CIITA IFNG IL10 IL1B IL6 TLR4
25
Show member pathways
12.35 IFNG IL10 IL2 IL4 IL6
26
Show member pathways
12.33 CXCL8 IFNG IL1B IL4 IL6 TLR4
27 12.31 CXCL8 IL10 IL1B IL6 TNF
28 12.26 IFNG IL6 TLR4 TNF
29 12.17 IFNG IL10 IL2 IL4 IL6 TNF
30 12.16 CXCL8 IL10 IL1B IL4 IL6 TNF
31
Show member pathways
12.08 IFNG IL1B IL2 IL4
32
Show member pathways
12.08 IFNG IL1B IL4 IL6 TLR4
33 12.06 IL1B IL6 LTA TNF
34 12.05 CXCL8 IFNG IL1B IL6
35 12.05 CXCL8 IL1B LTA TLR4 TNF
36 12.03 CXCL8 IFNG IL1B IL6 TLR4 TNF
37 12.02 CXCL8 IL1B IL6 TNF
38 12.02 CXCL8 IFNG IL10 IL1B IL6 TLR4
39 12.01 IL1B IL4 IL6 TNF
40 12 CXCL8 IFNG IL1B IL6 TLR4
41 12 CXCL8 IFNG IL1B IL2 IL4 IL6
42 11.98 IFNG IL10 IL2 IL6
43 11.98 CXCL8 IFNG IL2 IL4 IL6
44
Show member pathways
11.94 CXCL8 IFNG IL2 IL4 TNF
45 11.93 IFNG IL6 TLR4
46 11.92 IFNG IL10 IL1B IL2 IL6 TNF
47 11.9 CXCL8 IL2 TLR4
48
Show member pathways
11.9 CXCL8 IL6 TLR4
49 11.86 IL10 IL4 IL6 LTA TLR4 TNF
50
Show member pathways
11.85 CXCL8 IL2 LTA

GO Terms for Toxic Shock Syndrome

Cellular components related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 C1S CXCL8 HMGB1 IFNG IL10 IL1B
2 external side of plasma membrane GO:0009897 9.55 IFNG IL4 IL6 TLR4 TNF
3 extracellular space GO:0005615 9.36 CXCL8 HMGB1 IFNG IL10 IL1B IL2

Biological processes related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 IL1B IL6 TLR4 TNF
2 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.95 IL10 IL1B IL4 IL6 TNF
3 defense response to Gram-positive bacterium GO:0050830 9.92 IL6 LTA TNF
4 response to nutrient GO:0007584 9.92 IL4 LTA SERPINC1
5 regulation of insulin secretion GO:0050796 9.91 IFNG IL1B TNF
6 positive regulation of JNK cascade GO:0046330 9.91 HMGB1 IL1B TLR4 TNF
7 positive regulation of protein phosphorylation GO:0001934 9.91 IFNG IL1B IL2 IL4 TNF
8 cellular response to lipopolysaccharide GO:0071222 9.91 CXCL8 IFNG IL10 IL6 TLR4 TNF
9 neutrophil chemotaxis GO:0030593 9.9 CXCL8 IFNG IL1B
10 response to glucocorticoid GO:0051384 9.9 HMGB1 IL10 IL6 TNF
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 IFNG IL2 IL4 IL6
12 positive regulation of T cell proliferation GO:0042102 9.89 IFNG IL1B IL2 IL4 IL6
13 positive regulation of tumor necrosis factor production GO:0032760 9.88 HMGB1 IFNG TLR4
14 humoral immune response GO:0006959 9.87 IFNG IL6 LTA TNF
15 positive regulation of B cell proliferation GO:0030890 9.86 IL2 IL4 TLR4
16 inflammatory response GO:0006954 9.86 CIITA CXCL8 HMGB1 IL10 IL1B IL6
17 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.85 IL1B IL2 IL4
18 lipopolysaccharide-mediated signaling pathway GO:0031663 9.85 IL1B TLR4 TNF
19 positive regulation of activated T cell proliferation GO:0042104 9.84 HMGB1 IL2 IL4
20 defense response to protozoan GO:0042832 9.84 IFNG IL10 IL4 IL6
21 positive regulation of interleukin-8 production GO:0032757 9.83 IL1B TLR4 TNF
22 negative regulation of interleukin-6 production GO:0032715 9.83 IL10 TLR4 TNF
23 negative regulation of interferon-gamma production GO:0032689 9.82 HMGB1 IL10 TLR4
24 positive regulation of interleukin-12 production GO:0032735 9.81 HMGB1 IFNG TLR4
25 positive regulation of interleukin-10 production GO:0032733 9.81 HMGB1 IL4 TLR4
26 positive regulation of NF-kappaB import into nucleus GO:0042346 9.8 IL1B TLR4 TNF
27 positive regulation of chemokine production GO:0032722 9.8 IL6 TLR4 TNF
28 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.79 IFNG IL1B TNF
29 negative regulation of growth of symbiont in host GO:0044130 9.78 IFNG IL10 LTA TNF
30 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 IFNG IL1B IL6 TLR4 TNF
31 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.76 IL10 IL1B TNF
32 cellular response to hepatocyte growth factor stimulus GO:0035729 9.75 IL10 IL6
33 negative regulation of collagen biosynthetic process GO:0032966 9.75 CIITA IL6
34 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.75 IL1B TNF
35 response to molecule of bacterial origin GO:0002237 9.75 CXCL8 IL10
36 positive regulation of interferon-alpha production GO:0032727 9.75 HMGB1 TLR4
37 positive regulation of immunoglobulin secretion GO:0051024 9.74 IL2 IL6
38 positive regulation of protein import into nucleus, translocation GO:0033160 9.74 IFNG IL6
39 negative regulation of interleukin-17 production GO:0032700 9.74 IFNG TLR4
40 negative regulation of lipid storage GO:0010888 9.74 IL6 TNF
41 regulation of defense response to virus by host GO:0050691 9.74 IFNG IL1B
42 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.73 IFNG IL1B
43 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.73 TLR4 TNF
44 endothelial cell apoptotic process GO:0072577 9.73 IL10 TNF
45 positive regulation of isotype switching to IgG isotypes GO:0048304 9.73 IFNG IL2 IL4
46 regulation of establishment of endothelial barrier GO:1903140 9.72 IL1B TNF
47 negative regulation of cytokine secretion involved in immune response GO:0002740 9.72 IL10 TNF
48 positive regulation of interleukin-12 biosynthetic process GO:0045084 9.72 IFNG TLR4
49 positive regulation of interferon-gamma production GO:0032729 9.72 IL1B IL2 LTA TLR4 TNF
50 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.71 IL6 TNF

Molecular functions related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 CXCL8 HMGB1 IFNG IL10 IL1B IL2
2 growth factor activity GO:0008083 9.26 IL10 IL2 IL4 IL6

Sources for Toxic Shock Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....